Medicines Co
MDCO
MDCO was delisted on the 3rd of January, 2020.
190 hedge funds and large institutions have $3.37B invested in Medicines Co in 2017 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 70 increasing their positions, 73 reducing their positions, and 30 closing their positions.
4% less capital invested
Capital invested by funds: $3.5B → $3.37B (-$128M)
4% less repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 73
6% less funds holding
Funds holding: 202 → 190 (-12)
17% less funds holding in top 10
Funds holding in top 10: 12 → 10 (-2)
20% less call options, than puts
Call options by funds: $40.8M | Put options by funds: $50.9M
33% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$33.7M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$22.5M |
| 3 |
PC
PointState Capital
New York
|
+$21.3M |
| 4 |
SPC
Slate Path Capital
New York
|
+$20.8M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$19.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
-$70.6M |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$27M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$21.1M |
| 4 |
CM
Corvex Management
New York
|
-$19.7M |
| 5 |
AA
Antipodean Advisors
New York
|
-$14.7M |
MDCO Hedge Fund Activity: Q3 2017 in Review
190 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Medicines Co (MDCO) for Q3 2017, worth a combined $3.37B — down 3.7% from $3.5B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of MDCO and 20 opened new positions — a net loss of 10 holders — while 73 trimmed existing stakes and 70 added.
The largest buyer was Goldman Sachs, adding an estimated $33.7M. The largest seller was Iridian Asset Management, cutting an estimated $70.6M.
- 190 institutional investors held Medicines Co (MDCO) as of Q3 2017, down from 202 in Q2 2017.
- Funds reported $3.37B of Medicines Co stock for Q3 2017, down 3.7% quarter-over-quarter.
- 20 funds opened new Medicines Co positions in Q3 2017 and 30 closed out, a net change of -10 holders.
- The largest Medicines Co buyer in Q3 2017 was Goldman Sachs, an estimated $33.7M added.
- The largest Medicines Co seller in Q3 2017 was Iridian Asset Management, an estimated $70.6M sold.
Based on aggregated 13F filings for Q3 2017.